RESTORING IMMUNE TOLERANCE
Allero Therapeutics develops next generation immunotherapies for allergic and autoimmune disease patients, with a focus on food-related immune disorders. Its proprietary SOMIT (Specific OroMucosal ImmunoTherapy) technology is designed to induce long-lasting antigen-specific tolerance.
Allero Therapeutics is a venture-backed, biopharmaceutical company that develops next generation immunotherapies for food-related immune disorders.
Based on ideas of the founders, the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction.
Allero started to develop an R&D pipeline with a focus on a celiac disease product and a food allergy product, and we are looking for other pipeline opportunities to be developed in partnerships.